| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethanol | 31 | 2012 | 86 | 4.960 |
Why?
|
| Liver | 42 | 2013 | 157 | 3.860 |
Why?
|
| Proteasome Endopeptidase Complex | 28 | 2017 | 32 | 3.330 |
Why?
|
| Hepatocytes | 29 | 2012 | 85 | 2.360 |
Why?
|
| Animals | 73 | 2022 | 1875 | 2.360 |
Why?
|
| Proteasome Inhibitors | 9 | 2013 | 10 | 2.090 |
Why?
|
| Liver Diseases, Alcoholic | 15 | 2012 | 29 | 2.030 |
Why?
|
| Boronic Acids | 10 | 2013 | 10 | 1.820 |
Why?
|
| Pyrazines | 10 | 2013 | 17 | 1.810 |
Why?
|
| Inclusion Bodies | 17 | 2010 | 20 | 1.800 |
Why?
|
| Epithelial Cells | 5 | 2022 | 49 | 1.690 |
Why?
|
| S-Adenosylmethionine | 11 | 2012 | 17 | 1.650 |
Why?
|
| Mouth Mucosa | 5 | 2021 | 13 | 1.580 |
Why?
|
| Rats | 33 | 2013 | 571 | 1.440 |
Why?
|
| Cytochrome P-450 CYP2E1 | 11 | 2011 | 11 | 1.330 |
Why?
|
| Multienzyme Complexes | 9 | 2010 | 12 | 1.250 |
Why?
|
| Male | 54 | 2012 | 3671 | 1.150 |
Why?
|
| Cysteine Endopeptidases | 10 | 2011 | 13 | 1.140 |
Why?
|
| Rats, Wistar | 22 | 2012 | 55 | 1.060 |
Why?
|
| Disease Models, Animal | 17 | 2015 | 231 | 1.040 |
Why?
|
| Limbus Corneae | 3 | 2022 | 5 | 1.030 |
Why?
|
| Epigenesis, Genetic | 6 | 2009 | 36 | 1.010 |
Why?
|
| Central Nervous System Depressants | 6 | 2010 | 14 | 0.960 |
Why?
|
| Keratins | 10 | 2010 | 11 | 0.960 |
Why?
|
| Mice | 37 | 2012 | 746 | 0.950 |
Why?
|
| Corneal Diseases | 2 | 2022 | 9 | 0.870 |
Why?
|
| Proteins | 10 | 2011 | 41 | 0.820 |
Why?
|
| Histones | 8 | 2012 | 13 | 0.800 |
Why?
|
| Protease Inhibitors | 4 | 2011 | 11 | 0.790 |
Why?
|
| Gene Expression Regulation | 9 | 2019 | 120 | 0.780 |
Why?
|
| Enzyme Inhibitors | 6 | 2012 | 53 | 0.750 |
Why?
|
| Ubiquitins | 10 | 2012 | 14 | 0.730 |
Why?
|
| Toll-Like Receptors | 3 | 2011 | 16 | 0.720 |
Why?
|
| Mice, Inbred C3H | 21 | 2012 | 39 | 0.710 |
Why?
|
| Cells, Cultured | 15 | 2021 | 234 | 0.690 |
Why?
|
| Oxidative Stress | 9 | 2013 | 102 | 0.630 |
Why?
|
| Liver Neoplasms | 9 | 2012 | 63 | 0.600 |
Why?
|
| Blotting, Western | 17 | 2012 | 110 | 0.600 |
Why?
|
| Ubiquitin | 10 | 2012 | 10 | 0.580 |
Why?
|
| Epithelium, Corneal | 2 | 2017 | 5 | 0.580 |
Why?
|
| Bortezomib | 10 | 2013 | 10 | 0.580 |
Why?
|
| Fatty Liver | 3 | 2013 | 59 | 0.560 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 14 | 2011 | 29 | 0.560 |
Why?
|
| Gene Expression | 5 | 2010 | 77 | 0.560 |
Why?
|
| Up-Regulation | 6 | 2011 | 94 | 0.520 |
Why?
|
| Signal Transduction | 7 | 2011 | 246 | 0.520 |
Why?
|
| Transcription Factors | 6 | 2012 | 53 | 0.510 |
Why?
|
| Aldehydes | 5 | 2022 | 8 | 0.510 |
Why?
|
| Rabbits | 4 | 2022 | 48 | 0.510 |
Why?
|
| Stem Cells | 3 | 2022 | 19 | 0.490 |
Why?
|
| Cell Nucleus | 5 | 2012 | 38 | 0.470 |
Why?
|
| Corneal Injuries | 1 | 2015 | 2 | 0.450 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 8 | 0.450 |
Why?
|
| Burns, Chemical | 1 | 2015 | 4 | 0.450 |
Why?
|
| Organ Preservation | 2 | 2013 | 2 | 0.440 |
Why?
|
| Organ Preservation Solutions | 2 | 2013 | 2 | 0.440 |
Why?
|
| Humans | 23 | 2021 | 6794 | 0.430 |
Why?
|
| Liver Diseases | 5 | 2010 | 19 | 0.420 |
Why?
|
| Dihydropyridines | 10 | 2010 | 11 | 0.410 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 14 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 27 | 0.410 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 28 | 0.410 |
Why?
|
| Chemical and Drug Induced Liver Injury | 4 | 2012 | 14 | 0.390 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 12 | 2012 | 90 | 0.380 |
Why?
|
| Fatty Acids | 1 | 2012 | 25 | 0.360 |
Why?
|
| Cholesterol | 1 | 2012 | 37 | 0.360 |
Why?
|
| Triglycerides | 1 | 2012 | 58 | 0.360 |
Why?
|
| Protein Subunits | 3 | 2010 | 7 | 0.350 |
Why?
|
| Porphobilinogen Synthase | 1 | 2011 | 1 | 0.350 |
Why?
|
| Alcoholism | 2 | 2009 | 25 | 0.340 |
Why?
|
| Heat-Shock Proteins | 3 | 2005 | 9 | 0.340 |
Why?
|
| Cell Cycle Proteins | 3 | 2007 | 22 | 0.320 |
Why?
|
| RNA, Messenger | 13 | 2011 | 190 | 0.300 |
Why?
|
| Nutritional Status | 1 | 2010 | 64 | 0.300 |
Why?
|
| Carcinoma, Hepatocellular | 7 | 2012 | 34 | 0.300 |
Why?
|
| Methylation | 6 | 2012 | 9 | 0.290 |
Why?
|
| Betaine | 5 | 2012 | 6 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 155 | 0.290 |
Why?
|
| Reperfusion Injury | 4 | 2013 | 7 | 0.280 |
Why?
|
| Adenosine Triphosphatases | 3 | 2005 | 6 | 0.280 |
Why?
|
| Precancerous Conditions | 4 | 2011 | 12 | 0.280 |
Why?
|
| Keratin-8 | 2 | 2006 | 2 | 0.270 |
Why?
|
| Histone Acetyltransferases | 1 | 2007 | 1 | 0.260 |
Why?
|
| Keratin-18 | 1 | 2006 | 2 | 0.250 |
Why?
|
| Transplantation, Autologous | 2 | 2017 | 5 | 0.240 |
Why?
|
| Hepatitis, Animal | 1 | 2005 | 3 | 0.240 |
Why?
|
| DNA Primers | 3 | 2010 | 23 | 0.230 |
Why?
|
| Chlormethiazole | 8 | 2006 | 8 | 0.230 |
Why?
|
| Okadaic Acid | 1 | 2004 | 1 | 0.220 |
Why?
|
| Acetylation | 3 | 2009 | 10 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2010 | 88 | 0.200 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2006 | 24 | 0.200 |
Why?
|
| Protein Biosynthesis | 1 | 2002 | 9 | 0.190 |
Why?
|
| Mice, Knockout | 6 | 2012 | 150 | 0.190 |
Why?
|
| Liver Transplantation | 2 | 2013 | 8 | 0.190 |
Why?
|
| Tissue Engineering | 2 | 2020 | 4 | 0.190 |
Why?
|
| Periodicity | 1 | 2002 | 8 | 0.190 |
Why?
|
| Mallory Bodies | 2 | 2012 | 2 | 0.190 |
Why?
|
| Oxidoreductases | 1 | 2022 | 1 | 0.190 |
Why?
|
| Hepatitis C | 2 | 2012 | 19 | 0.180 |
Why?
|
| Tretinoin | 1 | 2022 | 30 | 0.180 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2002 | 16 | 0.180 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 38 | 0.180 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 70 | 0.180 |
Why?
|
| Feeding Behavior | 3 | 2011 | 38 | 0.170 |
Why?
|
| Cytokines | 2 | 2011 | 80 | 0.160 |
Why?
|
| Enzyme Induction | 3 | 2006 | 9 | 0.160 |
Why?
|
| Base Sequence | 2 | 2010 | 65 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 54 | 0.150 |
Why?
|
| Preservation, Biological | 1 | 2019 | 2 | 0.150 |
Why?
|
| Down-Regulation | 2 | 2012 | 57 | 0.150 |
Why?
|
| Antigens, Differentiation | 1 | 2019 | 6 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 18 | 0.150 |
Why?
|
| Chymotrypsin | 3 | 2009 | 5 | 0.150 |
Why?
|
| Reactive Oxygen Species | 2 | 2011 | 45 | 0.150 |
Why?
|
| Adipose Tissue | 1 | 2019 | 69 | 0.140 |
Why?
|
| Muscle, Skeletal | 1 | 1999 | 75 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2019 | 101 | 0.140 |
Why?
|
| Peptide Hydrolases | 3 | 2003 | 7 | 0.140 |
Why?
|
| Aging | 1 | 1999 | 105 | 0.140 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 38 | 0.140 |
Why?
|
| DNA Damage | 2 | 2009 | 20 | 0.140 |
Why?
|
| Glutathione | 2 | 2010 | 14 | 0.140 |
Why?
|
| Phosphoproteins | 2 | 2010 | 9 | 0.130 |
Why?
|
| Regeneration | 1 | 2017 | 5 | 0.130 |
Why?
|
| Phosphorylation | 4 | 2011 | 73 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 118 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 2 | 2009 | 14 | 0.130 |
Why?
|
| Rats, Zucker | 2 | 2013 | 8 | 0.130 |
Why?
|
| In Situ Hybridization | 2 | 2007 | 13 | 0.130 |
Why?
|
| Protein Conformation | 2 | 2010 | 5 | 0.120 |
Why?
|
| Protein Binding | 3 | 2012 | 29 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2011 | 44 | 0.120 |
Why?
|
| In Vitro Techniques | 4 | 2011 | 72 | 0.110 |
Why?
|
| Dicarbethoxydihydrocollidine | 4 | 2012 | 4 | 0.110 |
Why?
|
| Catecholamines | 2 | 2004 | 7 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2012 | 26 | 0.100 |
Why?
|
| Solutions | 1 | 2013 | 3 | 0.100 |
Why?
|
| Hypoxia | 2 | 2004 | 37 | 0.100 |
Why?
|
| Phenotype | 3 | 2010 | 91 | 0.100 |
Why?
|
| Cold Ischemia | 1 | 2013 | 1 | 0.100 |
Why?
|
| Leupeptins | 1 | 2013 | 4 | 0.100 |
Why?
|
| Inactivation, Metabolic | 2 | 2010 | 2 | 0.100 |
Why?
|
| Adenosine Triphosphate | 2 | 2003 | 17 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 11 | 0.100 |
Why?
|
| Microscopy, Confocal | 2 | 2004 | 11 | 0.100 |
Why?
|
| Methyltransferases | 1 | 2012 | 2 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2012 | 1 | 0.090 |
Why?
|
| Propranolol | 2 | 2009 | 5 | 0.090 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2012 | 6 | 0.090 |
Why?
|
| Apolipoproteins | 1 | 2012 | 1 | 0.090 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2012 | 2 | 0.090 |
Why?
|
| Intestinal Absorption | 1 | 2012 | 7 | 0.090 |
Why?
|
| Administration, Oral | 4 | 2009 | 54 | 0.090 |
Why?
|
| Animal Nutritional Physiological Phenomena | 2 | 2010 | 5 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 33 | 0.090 |
Why?
|
| Mice, Inbred Strains | 2 | 2002 | 21 | 0.090 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2012 | 4 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 2 | 0.090 |
Why?
|
| Lysine | 2 | 2012 | 3 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2011 | 20 | 0.090 |
Why?
|
| Time Factors | 2 | 2010 | 321 | 0.090 |
Why?
|
| Chromatography | 1 | 2011 | 1 | 0.090 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 13 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 12 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 65 | 0.090 |
Why?
|
| Carcinogens | 2 | 2008 | 11 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 72 | 0.090 |
Why?
|
| Catechin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Metalloendopeptidases | 1 | 2011 | 2 | 0.090 |
Why?
|
| tau Proteins | 1 | 2011 | 2 | 0.090 |
Why?
|
| Immunoproteins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Quercetin | 1 | 2011 | 9 | 0.080 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2010 | 1 | 0.080 |
Why?
|
| Glutathione Reductase | 1 | 2010 | 1 | 0.080 |
Why?
|
| Glutathione Synthase | 1 | 2010 | 1 | 0.080 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 2 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 3 | 0.080 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2008 | 11 | 0.080 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2010 | 2 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 30 | 0.080 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Methionine Adenosyltransferase | 1 | 2010 | 8 | 0.080 |
Why?
|
| Female | 5 | 2012 | 4060 | 0.080 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2010 | 2 | 0.080 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2010 | 11 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 45 | 0.080 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2010 | 12 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 16 | 0.080 |
Why?
|
| Diet | 3 | 2009 | 111 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2012 | 258 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 156 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 11 | 0.080 |
Why?
|
| Biomarkers | 1 | 2011 | 214 | 0.080 |
Why?
|
| Catalytic Domain | 1 | 2009 | 1 | 0.080 |
Why?
|
| Myocardium | 2 | 2006 | 25 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 8 | 0.080 |
Why?
|
| Body Weight | 3 | 2011 | 90 | 0.080 |
Why?
|
| RNA, Untranslated | 1 | 2009 | 2 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 40 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 14 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2011 | 8 | 0.070 |
Why?
|
| Carboxylic Acids | 1 | 2008 | 1 | 0.070 |
Why?
|
| Thioacetamide | 2 | 2006 | 2 | 0.070 |
Why?
|
| Acute Disease | 1 | 2009 | 91 | 0.070 |
Why?
|
| Sirtuins | 1 | 2008 | 1 | 0.070 |
Why?
|
| Stilbenes | 1 | 2008 | 2 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 65 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2008 | 21 | 0.070 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2006 | 4 | 0.070 |
Why?
|
| Drug Antagonism | 1 | 2008 | 2 | 0.070 |
Why?
|
| Cell Fractionation | 1 | 2008 | 5 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2009 | 167 | 0.070 |
Why?
|
| Mitochondria, Liver | 3 | 2013 | 5 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2008 | 20 | 0.070 |
Why?
|
| Inflammation | 1 | 2009 | 143 | 0.070 |
Why?
|
| Models, Biological | 2 | 2005 | 64 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2013 | 48 | 0.070 |
Why?
|
| Apoptosis | 1 | 2009 | 179 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Growth Substances | 1 | 2007 | 10 | 0.070 |
Why?
|
| Organ Size | 3 | 2012 | 31 | 0.060 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2007 | 1 | 0.060 |
Why?
|
| Liver Extracts | 1 | 2007 | 2 | 0.060 |
Why?
|
| Allyl Compounds | 1 | 2006 | 1 | 0.060 |
Why?
|
| Sulfides | 1 | 2006 | 1 | 0.060 |
Why?
|
| Polyubiquitin | 1 | 2006 | 1 | 0.060 |
Why?
|
| Protein Carbonylation | 1 | 2006 | 1 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2006 | 10 | 0.060 |
Why?
|
| Cell Survival | 1 | 2006 | 33 | 0.060 |
Why?
|
| Iron | 1 | 2006 | 35 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 21 | 0.060 |
Why?
|
| Chymases | 2 | 2005 | 2 | 0.060 |
Why?
|
| Serine Endopeptidases | 2 | 2005 | 10 | 0.060 |
Why?
|
| Sequestosome-1 Protein | 1 | 2005 | 3 | 0.060 |
Why?
|
| Pyridines | 3 | 2012 | 24 | 0.060 |
Why?
|
| Laminin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Integrins | 1 | 2005 | 4 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2005 | 1 | 0.060 |
Why?
|
| RNA Interference | 1 | 2005 | 11 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 7 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2005 | 15 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2005 | 56 | 0.050 |
Why?
|
| Xenobiotics | 1 | 2004 | 1 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2004 | 12 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 84 | 0.050 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2004 | 2 | 0.050 |
Why?
|
| Actins | 1 | 2004 | 28 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2004 | 54 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2004 | 48 | 0.050 |
Why?
|
| Microtubules | 1 | 2003 | 1 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cell-Free System | 1 | 2002 | 2 | 0.050 |
Why?
|
| Mutation | 1 | 2003 | 97 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 4 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 4 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 8 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 19 | 0.050 |
Why?
|
| NAD | 1 | 2002 | 3 | 0.050 |
Why?
|
| Antigen Presentation | 2 | 2012 | 3 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 30 | 0.050 |
Why?
|
| Spiro Compounds | 1 | 2001 | 1 | 0.050 |
Why?
|
| Pyrans | 1 | 2001 | 4 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2001 | 8 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 59 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2012 | 23 | 0.040 |
Why?
|
| Cytoplasm | 2 | 2011 | 7 | 0.040 |
Why?
|
| GABA Modulators | 3 | 2005 | 3 | 0.040 |
Why?
|
| Malondialdehyde | 2 | 2011 | 6 | 0.040 |
Why?
|
| Liver Regeneration | 2 | 2012 | 10 | 0.040 |
Why?
|
| Atrophy | 1 | 1999 | 7 | 0.040 |
Why?
|
| Rats, Inbred Strains | 1 | 1999 | 49 | 0.040 |
Why?
|
| Chondrocytes | 1 | 2019 | 1 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2019 | 4 | 0.040 |
Why?
|
| Adipocytes | 1 | 2019 | 31 | 0.040 |
Why?
|
| Alanine Transaminase | 2 | 2011 | 10 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 14 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2006 | 5 | 0.030 |
Why?
|
| Chromatography, Liquid | 2 | 2006 | 6 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2005 | 6 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 2 | 2005 | 7 | 0.030 |
Why?
|
| Transfection | 2 | 2005 | 56 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2005 | 39 | 0.030 |
Why?
|
| Antibodies | 2 | 2003 | 16 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2013 | 2 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2013 | 5 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2013 | 12 | 0.020 |
Why?
|
| Adiponectin | 1 | 2013 | 6 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 6 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 17 | 0.020 |
Why?
|
| Response Elements | 1 | 2012 | 8 | 0.020 |
Why?
|
| Methionine | 1 | 2012 | 2 | 0.020 |
Why?
|
| Interferons | 1 | 2012 | 3 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2012 | 9 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2012 | 1 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2012 | 3 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2012 | 5 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2012 | 21 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 7 | 0.020 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2012 | 10 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2012 | 13 | 0.020 |
Why?
|
| Sarcosine | 1 | 2011 | 1 | 0.020 |
Why?
|
| Choline | 1 | 2011 | 7 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 19 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 23 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 282 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2011 | 5 | 0.020 |
Why?
|
| Gastrointestinal Agents | 1 | 2011 | 6 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2011 | 16 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2011 | 13 | 0.020 |
Why?
|
| Antioxidants | 1 | 2011 | 37 | 0.020 |
Why?
|
| Brain | 1 | 2011 | 94 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 124 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 72 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 58 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 3 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 5 | 0.020 |
Why?
|
| Thionucleosides | 1 | 2008 | 1 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 51 | 0.020 |
Why?
|
| Flavanones | 1 | 2008 | 1 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2009 | 20 | 0.020 |
Why?
|
| Sirtuin 1 | 1 | 2008 | 8 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2008 | 51 | 0.020 |
Why?
|
| Zalcitabine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 2 | 0.020 |
Why?
|
| RNA | 1 | 2008 | 25 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2006 | 6 | 0.020 |
Why?
|
| Muscle Cells | 1 | 2006 | 5 | 0.020 |
Why?
|
| Kinetics | 1 | 2006 | 69 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Griseofulvin | 1 | 2006 | 1 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 6 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 17 | 0.020 |
Why?
|
| alpha-Macroglobulins | 1 | 2006 | 1 | 0.020 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2006 | 1 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2006 | 2 | 0.020 |
Why?
|
| Glypicans | 1 | 2006 | 2 | 0.020 |
Why?
|
| Fatty Acid Synthases | 1 | 2006 | 6 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2006 | 6 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2005 | 1 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2005 | 1 | 0.010 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2005 | 2 | 0.010 |
Why?
|
| Quinazolines | 1 | 2005 | 4 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2005 | 5 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 4 | 0.010 |
Why?
|
| Valosin Containing Protein | 1 | 2005 | 2 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 11 | 0.010 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2005 | 4 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 6 | 0.010 |
Why?
|
| Transcription Factor TFIIH | 1 | 2004 | 1 | 0.010 |
Why?
|
| Adrenomedullin | 1 | 2004 | 1 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 5 | 0.010 |
Why?
|
| Phenoxybenzamine | 1 | 2004 | 1 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 10 | 0.010 |
Why?
|
| Peptides | 1 | 2004 | 19 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2004 | 25 | 0.010 |
Why?
|
| Oxygen | 1 | 2004 | 44 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2004 | 3 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 2004 | 7 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2004 | 9 | 0.010 |
Why?
|
| Ephedrine | 1 | 2003 | 1 | 0.010 |
Why?
|
| Caffeine | 1 | 2003 | 3 | 0.010 |
Why?
|
| Lumicolchicines | 1 | 2003 | 1 | 0.010 |
Why?
|
| Nocodazole | 1 | 2003 | 1 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 26 | 0.010 |
Why?
|
| Colchicine | 1 | 2003 | 4 | 0.010 |
Why?
|
| Necrosis | 1 | 2003 | 30 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 36 | 0.010 |
Why?
|
| Weight Gain | 1 | 2003 | 28 | 0.010 |
Why?
|
| Weight Loss | 1 | 2003 | 35 | 0.010 |
Why?
|
| Galactosamine | 1 | 2001 | 1 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2001 | 2 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 8 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2001 | 9 | 0.010 |
Why?
|